In vivo safety and biodistribution profile of Klotho-enhanced human urine-derived stem cells for clinical application
Sang-Heon Kim, Sung-Hoon Lee, Jeong-Ah Jin, Hyung-Joon So, Jae-Ung Lee, Min-Jae Ji, Eun-Joong Kwon, Pyo-Sung Han, Hong-Ki Lee, Tae-Wook Kang · 2023
Read In vivo safety and biodistribution profile of Klotho-enhanced human urine-derived stem cells for clinical application by Sang-Heon Kim, Sung-Hoon Lee, Jeong-Ah Jin, Hyung-Joon So, Jae-Ung Lee, Min-Jae Ji, Eun-Joong Kwon, Pyo-Sung Han, Hong-Ki Lee, Tae-Wook Kang (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10712141.txt.
Description
Sang-Heon Kim and co-authors checked the safety of treated stem cells from human urine in this 2023 study. Such cells are easy to collect and may help kidney disease, since they come from the kidney system. The team boosted a kidney-protective factor in the cells and set up clean, large-scale growth.
Mice were watched after single and repeated doses given through a vein. No harmful effects showed in checks of body tissue and blood. The cells reached injured kidney tissue and stayed in blood and organs for about three days, clearing from most organs within two weeks. Long watch over 26 weeks checked for tumor growth. The study backs later clinical tests.
Catalog record
| CREATOR | Sang-Heon Kim, Sung-Hoon Lee, Jeong-Ah Jin, Hyung-Joon So, Jae-Ung Lee, Min-Jae Ji, Eun-Joong Kwon, Pyo-Sung Han, Hong-Ki Lee, Tae-Wook Kang |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |